Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK™, Genentech Inc.) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.
On August 16, 2019, the Food and Drug Administration approved fedratinib (INREBIC®, Impact Biomedicines, Inc.) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). Read more.
In the latest ASCO in Action Podcast, Lisa Lacasse, President of the American Cancer Society Cancer Action Network (ACS CAN), joins Dr. Hudis to discuss the critical importance of advocacy and ACS CAN’s partnership with ASCO in reducing the cancer burden.
When patients ask “what happens next,” the ASCO Answers Cancer Survivorship Guide is there to provide answers and support”. The guide includes a blank treatment summary and survivorship care plan and also covers important topics in cancer survivorship, including physical, financial, and reproductive challenges, follow-up care, and rehabilitation. ASCO members save 20%. Free domestic shipping. ASCO members save 20%. Free domestic shipping.
Conquer Cancer®, the ASCO Foundation, has awarded more than $126 million through nearly 2,100 grants and awards to medical students, trainees, young scientists, and oncologists at all stages of their careers. A comprehensive portfolio of funding opportunities is available for various career stages. Learn more and apply today.
On August 5, ASCO published the Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer Guideline.
The Centers for Medicare & Medicaid Services (CMS) announced that Medicare will now cover all Food and Drug Administration (FDA)-approved Chimeric Antigen Receptor T-cell (CAR T-cell) therapy delivered in inpatient facilities.
The Centers for Medicare & Medicaid Services released its proposed rule for the 2020 Medicare Physician Fee Schedule and other changes to Medicare Part B and the Quality Payment Program. ASCO’s preliminary analysis outlines important changes to Evaluation & Management coding and the Merit-Based Incentive Payment System.. Learn more.